Tokyo Tape
Sign in
← Kirin Holdings

Annual report

2503.TEDINET S100VH7L
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥2.34T2024-01-01 → 2024-12-31Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥1.99T2022-01-01 → 2022-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.82T2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.85T2020-01-01 → 2020-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥125.3bn2024-01-01 → 2024-12-31Cons.Operating profit loss IFRS
Operating income¥150.3bn2023-01-01 → 2023-12-31Cons.Operating profit loss IFRS
Profit before tax¥139.7bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥191.4bn2022-01-01 → 2022-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥99.6bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥124.5bn2020-01-01 → 2020-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥58.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥111.0bn2022-01-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥59.8bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥71.9bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥85.8bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS
Net income¥150.4bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS
Total assets¥3.35Tat 2024-12-31Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.54Tat 2022-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.47Tat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.46Tat 2020-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥1.82Tat 2024-12-31Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.53Tat 2024-12-31Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.18Tat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥980.0bnat 2022-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥894.2bnat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥838.6bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥118.6bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥149.5bnat 2021-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥161.7bnat 2020-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥242.8bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥135.6bn2022-01-01 → 2022-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥219.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥164.8bn2020-01-01 → 2020-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥329.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥10.4bn2022-01-01 → 2022-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥56.4bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥116.0bn2020-01-01 → 2020-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow¥58.1bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥167.8bn2022-01-01 → 2022-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥180.5bn2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥52.5bn2020-01-01 → 2020-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥71.872024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥135.082022-01-01 → 2022-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥71.732021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥85.572020-01-01 → 2020-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.862024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥135.072022-01-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥71.72021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥85.542020-01-01 → 2020-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,458.68at 2024-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,398.47at 2023-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,210.16at 2022-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,072.69at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,005.96at 2020-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio35.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio38.5%at 2022-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.2%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio34.1%at 2020-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE5.0%2024-01-01 → 2024-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE10.7%2023-01-01 → 2023-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE11.8%2022-01-01 → 2022-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE6.9%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE8.2%2020-01-01 → 2020-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees31,934at 2024-12-31Cons.Number of employees
Revenue¥194.6bn2024-01-01 → 2024-12-31StandaloneOperating revenue1
Revenue¥139.0bn2023-01-01 → 2023-12-31StandaloneOperating revenue1
Revenue¥152.8bn2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥139.5bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥138.8bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income¥114.5bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income¥64.4bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income¥60.4bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income¥62.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥76.9bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥73.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥72.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥332.2bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax¥77.2bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income−¥344.9bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income¥70.4bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥48.7bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income¥77.3bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥79.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.85Tat 2024-12-31StandaloneAssets
Total assets¥2.28Tat 2023-12-31StandaloneAssets
Total assets¥1.90Tat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.00Tat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.97Tat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥1.29Tat 2024-12-31StandaloneLiabilities
Total liabilities¥1.32Tat 2023-12-31StandaloneLiabilities
Net assets / equity¥561.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥964.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥951.1bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.01Tat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥987.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥12.2bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥20.2bnat 2023-12-31StandaloneCash and deposits
EPS (basic)¥-425.842024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥86.912023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥59.242022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥92.672021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥94.372020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥712024-01-01 → 2024-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥712023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥692022-01-01 → 2022-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥652021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥652020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥693.7at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,190.61at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,174.47at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,208.06at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,184.06at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio30.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio42.3%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE-45.2%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE7.3%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE5.0%2022-01-01 → 2022-12-31dStandaloneRate of return on equity (5-year summary)
ROE7.8%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE7.8%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued914,000,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued914,000,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,067at 2024-12-31StandaloneNumber of employees
Employees977at 2023-12-31StandaloneNumber of employees
Employees914at 2022-12-31dStandaloneNumber of employees
Employees1,156at 2021-12-31dStandaloneNumber of employees
Employees1,117at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 75
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2024-01-01 → 2024-12-31¥7.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-12-312113 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-12-31¥97.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-12-31¥21.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-12-31¥76.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-12-31¥362.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-12-31¥30m
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥10.4bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-12-31−¥86.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-12-31−¥86.4bn
Reconciling Itemsreconcilingsegment assetsat 2024-12-31−¥478.8bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥58.0bn
Alcoholic Beveragesreportable segmentcapex2024-01-01 → 2024-12-31¥39.0bn
Alcoholic Beveragesreportable segmentemployeesat 2024-12-318925 pure
Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-12-31¥1.08T
Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-12-31¥1.08T
Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥2.3bn
Alcoholic Beveragesreportable segmentsegment assetsat 2024-12-31¥1.37T
Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-12-31¥124.0bn
Health Sciencereportable segmentcapex2024-01-01 → 2024-12-31¥6.7bn
Health Sciencereportable segmentemployeesat 2024-12-315954 pure
Health Sciencereportable segmentrevenue2024-01-01 → 2024-12-31¥179.5bn
Health Sciencereportable segmentrevenue external2024-01-01 → 2024-12-31¥175.3bn
Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥4.2bn
Health Sciencereportable segmentsegment assetsat 2024-12-31¥764.1bn
Health Sciencereportable segmentsegment profit2024-01-01 → 2024-12-31−¥10.9bn
Non Alcoholic Beveragesreportable segmentcapex2024-01-01 → 2024-12-31¥20.9bn
Non Alcoholic Beveragesreportable segmentemployeesat 2024-12-317887 pure
Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-12-31¥567.8bn
Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-12-31¥564.9bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥3.0bn
Non Alcoholic Beveragesreportable segmentsegment assetsat 2024-12-31¥326.4bn
Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-12-31¥64.0bn
Pharmaceuticalsreportable segmentcapex2024-01-01 → 2024-12-31¥109.5bn
Pharmaceuticalsreportable segmentemployeesat 2024-12-315669 pure
Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-12-31¥495.6bn
Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-12-31¥495.3bn
Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥264m
Pharmaceuticalsreportable segmentsegment assetsat 2024-12-31¥1.01T
Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-12-31¥91.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2023-01-01 → 2023-12-31¥2.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-12-31¥94.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-12-31¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-12-31¥66.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-12-31¥510.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-12-31−¥60m
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥10.3bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-12-31−¥76.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-12-31−¥76.4bn
Reconciling Itemsreconcilingsegment assetsat 2023-12-31−¥719.8bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥54.2bn
Alcoholic Beveragesreportable segmentcapex2023-01-01 → 2023-12-31¥39.1bn
Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-12-31¥1.05T
Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-12-31¥1.05T
Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥2.3bn
Alcoholic Beveragesreportable segmentsegment assetsat 2023-12-31¥1.35T
Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-12-31¥119.9bn
Health Sciencereportable segmentcapex2023-01-01 → 2023-12-31¥10.1bn
Health Sciencereportable segmentrevenue2023-01-01 → 2023-12-31¥108.0bn
Health Sciencereportable segmentrevenue external2023-01-01 → 2023-12-31¥103.4bn
Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥4.7bn
Health Sciencereportable segmentsegment assetsat 2023-12-31¥473.7bn
Health Sciencereportable segmentsegment profit2023-01-01 → 2023-12-31−¥12.5bn
Non Alcoholic Beveragesreportable segmentcapex2023-01-01 → 2023-12-31¥24.2bn
Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-12-31¥518.9bn
Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-12-31¥516.2bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥2.8bn
Non Alcoholic Beveragesreportable segmentsegment assetsat 2023-12-31¥287.4bn
Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-12-31¥52.4bn
Pharmaceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥33.3bn
Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥442.2bn
Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥441.9bn
Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥351m
Pharmaceuticalsreportable segmentsegment assetsat 2023-12-31¥971.4bn
Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥96.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 2,393
ItemContextValueUnit
Revenue from external customers IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember516171000000JPY
Revenue from external customers IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember441882000000JPY
Revenue from external customers IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember103354000000JPY
Revenue from external customers IFRSPrior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember27847000000JPY
Revenue from external customers IFRSPrior1YearDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YearDuration2134393000000JPY
Intersegment revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember2336000000JPY
Intersegment revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember2771000000JPY
Intersegment revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember351000000JPY
Intersegment revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember4694000000JPY
Intersegment revenue IFRSPrior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember66241000000JPY
Intersegment revenue IFRSPrior1YearDuration_ReconcilingItemsMember-76393000000JPY
Intersegment revenue IFRSPrior1YearDuration－JPY
Revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember1047473000000JPY
Revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember518942000000JPY
Revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember442233000000JPY
Revenue IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember108048000000JPY
Revenue IFRSPrior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember94089000000JPY
Revenue IFRSPrior1YearDuration_ReconcilingItemsMember-76393000000JPY
Revenue IFRSPrior1YearDuration2134393000000JPY
Segment profit loss IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember119939000000JPY
Segment profit loss IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember52358000000JPY
Segment profit loss IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember95968000000JPY
Segment profit loss IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember-12535000000JPY
Segment profit loss IFRSPrior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-60000000JPY
Segment profit loss IFRSPrior1YearDuration_ReconcilingItemsMember-54175000000JPY
Segment profit loss IFRSPrior1YearDuration201495000000JPY
Other operating income IFRSPrior1YearDuration28835000000JPY
Other operating expenses IFRSPrior1YearDuration80036000000JPY
Finance income IFRSPrior1YearDuration9035000000JPY
Finance costs IFRSPrior1YearDuration10523000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YearDuration32773000000JPY
Gain on sale of equity accounted investees IFRSPrior1YearDuration15470000000JPY
Profit loss before tax IFRSPrior1YearDuration197049000000JPY
Assets IFRSPrior1YearInstant_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember1346528000000JPY
Assets IFRSPrior1YearInstant_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember287417000000JPY
Assets IFRSPrior1YearInstant_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember971375000000JPY
Assets IFRSPrior1YearInstant_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember473664000000JPY
Assets IFRSPrior1YearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember510397000000JPY
Assets IFRSPrior1YearInstant_ReconcilingItemsMember-719795000000JPY
Assets IFRSPrior1YearInstant2869585000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember35296000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember12719000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember20938000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember5172000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember3803000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_ReconcilingItemsMember9299000000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration87227000000JPY
Impairment losses pl IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember2476000000JPY
Impairment losses pl IFRSPrior1YearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass